Cinctive Capital Management LP Cuts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cinctive Capital Management LP lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 62.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,765 shares of the specialty pharmaceutical company’s stock after selling 80,382 shares during the quarter. Cinctive Capital Management LP owned 0.08% of Jazz Pharmaceuticals worth $5,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares during the last quarter. Centre Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $9,335,000. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth about $464,000. Franklin Resources Inc. increased its stake in Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after acquiring an additional 48,708 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 13.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock valued at $4,420,000 after acquiring an additional 4,332 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $124.99 on Wednesday. The firm’s 50-day moving average is $132.43 and its 200 day moving average is $122.90. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 1.04 and a beta of 0.44.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JAZZ. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Royal Bank of Canada decreased their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and an average target price of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock worth $4,022,825. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.